Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT ID: NCT03021460
Last Updated: 2026-01-20
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
ACTIVE_NOT_RECRUITING
Clinical Phase
PHASE1
Total Enrollment
20 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-01-31
Study Completion Date
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This phase I trial studies the best dose of ibrutinib when given together with pembrolizumab in treating patients with stage III-IV melanoma that cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
NCT02306850
Unresectable Malignant Neoplasm
Melanoma
Metastatic Melanoma
+2 more
COMPLETED
PHASE2
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
NCT03276832
Metastatic Melanoma
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
+1 more
COMPLETED
EARLY_PHASE1
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
NCT04007588
Melanoma Stage III
Melanoma Stage IV
WITHDRAWN
PHASE2
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
NCT02506153
Clinical Stage III Cutaneous Melanoma AJCC v8
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
+6 more
ACTIVE_NOT_RECRUITING
PHASE3
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
NCT02263508
Melanoma
TERMINATED
PHASE3
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVES:
I. To determine the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with advanced melanoma. (Phase I) II. To estimate the overall response rate treated at the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with advanced melanoma. (Dose expansion cohort)
SECONDARY OBJECTIVES:
I. To assess the safety and adverse-event profiles of combination of ibrutinib with pembrolizumab in patients with advanced melanoma.
II. To evaluate the overall response rate (ORR) in patients advanced melanoma receiving ibrutinib and pembrolizumab.
III. To evaluate the duration of response, progression-free survival (PFS), and overall survival (OS) in patients with advanced melanoma receiving ibrutinib and pembrolizumab.
IV. To assess the effect of treatment with ibrutinib and pembrolizumab on Th1/Th2 immune polarity.
EXPLORATORY OBJECTIVES:
I. To assess the CD8 T cell response to multiple melanoma-associated antigens, and to correlate CD8 T cell responses with changes in Th1/Th2 immune polarity.
II. To assess changes in plasma cytokines induced by treatment with ibrutinib and pembrolizumab.
III. To assess the change in potential biomarkers, such as tumor-bound and soluble PD-L1 levels and tumor-infiltrating lymphocytes, that may correlate with treatment responses.
OUTLINE: This is a dose-escalation study of ibrutinib.
Patients receive ibrutinib orally (PO) daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab intravenously (IV) over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years.
I. To determine the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with advanced melanoma. (Phase I) II. To estimate the overall response rate treated at the maximum tolerated dose of ibrutinib in combination with pembrolizumab in patients with advanced melanoma. (Dose expansion cohort)
SECONDARY OBJECTIVES:
I. To assess the safety and adverse-event profiles of combination of ibrutinib with pembrolizumab in patients with advanced melanoma.
II. To evaluate the overall response rate (ORR) in patients advanced melanoma receiving ibrutinib and pembrolizumab.
III. To evaluate the duration of response, progression-free survival (PFS), and overall survival (OS) in patients with advanced melanoma receiving ibrutinib and pembrolizumab.
IV. To assess the effect of treatment with ibrutinib and pembrolizumab on Th1/Th2 immune polarity.
EXPLORATORY OBJECTIVES:
I. To assess the CD8 T cell response to multiple melanoma-associated antigens, and to correlate CD8 T cell responses with changes in Th1/Th2 immune polarity.
II. To assess changes in plasma cytokines induced by treatment with ibrutinib and pembrolizumab.
III. To assess the change in potential biomarkers, such as tumor-bound and soluble PD-L1 levels and tumor-infiltrating lymphocytes, that may correlate with treatment responses.
OUTLINE: This is a dose-escalation study of ibrutinib.
Patients receive ibrutinib orally (PO) daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab intravenously (IV) over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
Stage IV Cutaneous Melanoma AJCC v6 and v7
Unresectable Melanoma
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (ibrutinib, pembrolizumab)
Patients receive ibrutinib PO daily on days 1-28 of cycle 1 and days 1-21 of cycle 2 and subsequent cycles. Patients also receive pembrolizumab IV over 30 minutes on day 8 of cycle 1 and day 1 of cycle 2 and subsequent cycles. Cycle 1 continues for 28 days and subsequent cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Ibrutinib
Intervention Type
DRUG
Given PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Pembrolizumab
Intervention Type
BIOLOGICAL
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ibrutinib
Given PO
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Pembrolizumab
Given IV
Intervention Type
BIOLOGICAL
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
BTK Inhibitor PCI-32765
CRA-032765
Imbruvica
PCI-32765
Keytruda
Lambrolizumab
MK-3475
SCH 900475
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
* At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as \>= 1.0 cm with computed tomography \[CT\] scan, CT component of a positron emission tomography \[PET\]/CT, or magnetic resonance imaging \[MRI\]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is \>= 1.5 cm when assessed by CT scan)
* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
* Provide informed written consent
* Patient is willing to undergo treatment and monitoring at the enrolling institution
* Willing to provide tissue and blood samples for correlative research purposes
* Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
* Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 therapy:
* Patient had disease progression on or within 6 months after anti-PD-1/anti-PD-L1 therapy in the metastatic setting OR
* Patient had disease progression within 6 months after the last dose of adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment
* Absolute neutrophil count (ANC) \>= 1000/mm\^3 (obtained =\< 14 days prior to registration)
* Platelet count \>= 75,000/mm\^3 (obtained =\< 14 days prior to registration)
* Criteria must be met without a transfusion =\< four weeks prior to registration
* Hemoglobin \>= 9.0 g/dL (obtained =\< 14 days prior to registration)
* Total bilirubin =\< 1.5 X upper limit of normal (ULN); if total bilirubin \> 1.5 X ULN then direct bilirubin =\< ULN (obtained =\< 14 days prior to registration)
* Aspartate aminotransferase (aspartate transaminase \[AST\]) and alanine aminotransferase (alanine transaminase \[ALT\]) =\< 2.5 x ULN OR =\< 5 X ULN for patients with liver metastases (obtained =\< 14 days prior to registration)
* Creatinine =\< 1.5 X ULN and creatinine clearance (CrCL) \>= 30 ml/min per Cockcroft Gault formula (obtained =\< 14 days prior to registration)
* Patients of childbearing potential only, negative urine pregnancy test done =\< 7 days prior to study registration
* At least one non-nodal lesion considered measurable by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (that is, a lesion whose longest diameter can be accurately measured as \>= 1.0 cm with computed tomography \[CT\] scan, CT component of a positron emission tomography \[PET\]/CT, or magnetic resonance imaging \[MRI\]) or at least one malignant lymph node is considered measurable by RECIST criteria (that is, its short axis is \>= 1.5 cm when assessed by CT scan)
* NOTE: tumor lesions in a previously irradiated area are not considered measurable disease
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
* Provide informed written consent
* Patient is willing to undergo treatment and monitoring at the enrolling institution
* Willing to provide tissue and blood samples for correlative research purposes
* Histologic or cytologic confirmation of unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
* Only if patient has had previous exposure to anti-PD-1 or anti-PD-L1 therapy:
* Patient had disease progression on or within 6 months after anti-PD-1/anti-PD-L1 therapy in the metastatic setting OR
* Patient had disease progression within 6 months after the last dose of adjuvant/neoadjuvant anti-PD-1/anti-PD-L1 treatment
* Absolute neutrophil count (ANC) \>= 1000/mm\^3 (obtained =\< 14 days prior to registration)
* Platelet count \>= 75,000/mm\^3 (obtained =\< 14 days prior to registration)
* Criteria must be met without a transfusion =\< four weeks prior to registration
* Hemoglobin \>= 9.0 g/dL (obtained =\< 14 days prior to registration)
* Total bilirubin =\< 1.5 X upper limit of normal (ULN); if total bilirubin \> 1.5 X ULN then direct bilirubin =\< ULN (obtained =\< 14 days prior to registration)
* Aspartate aminotransferase (aspartate transaminase \[AST\]) and alanine aminotransferase (alanine transaminase \[ALT\]) =\< 2.5 x ULN OR =\< 5 X ULN for patients with liver metastases (obtained =\< 14 days prior to registration)
* Creatinine =\< 1.5 X ULN and creatinine clearance (CrCL) \>= 30 ml/min per Cockcroft Gault formula (obtained =\< 14 days prior to registration)
* Patients of childbearing potential only, negative urine pregnancy test done =\< 7 days prior to study registration
Exclusion Criteria
* Any of the following:
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication; adequate contraception is defined as 2 methods of birth control (e.g., hormonal contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide) or prior surgical sterilization, or abstinence from heterosexual activity
* Prior treatment with ibrutinib or prior exposure to BTK inhibitors
* Uveal melanoma
* Current use of warfarin or other vitamin K antagonists
* Require continuous treatment with a strong CYP3A inhibitor
* Currently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registration
* Live vaccines within 28 days prior to study pre-registration
* Invasive surgical procedure within 28 days prior to study pre-registration
* History of clinically severe (e.g., requires chronic immunosuppressive therapy, \[e.g., cyclosporine A, tacrolimus\]) autoimmune disease (e.g., ulcerative colitis, lupus), or history of organ transplant
* Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
* Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction), or unable to swallow capsules
* Active central nervous system metastases and/or carcinomatous meningitis
* Note: Patients with untreated brain metastasis will be excluded; patients with previously treated brain metastases may participate provided they meet the following criteria:
* Inactive (without evidence of progression which is documented by CT or MRI within 90 days prior to registration), AND
* On =\< 10 mg/day prednisone or equivalent for at least 28 days prior pre-registration
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within =\< 180 days prior to registration, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
* Other active malignancy =\< 3 years prior to pre-registration; note: if there is a history of prior malignancy, the patient must not be receiving other specific treatment for cancer
* EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome =\< 6 months prior to pre-randomization
* Known bleeding disorders (von Willebrand's disease or hemophilia)
* History of ischemic stroke or intracranial hemorrhage =\< 180 days prior to pre-registration
* Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classification
* REGISTRATION- EXCLUSION
* Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
* Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody \[mAb\]) =\< 28 days prior to registration
* Received a strong cytochrome P450 (CYP) 3A inhibitor =\< 7 days prior to registration
* Concurrent systemic immunosuppressant therapy =\< 21 days prior to registration
* Recent infection requiring systemic antibiotic treatment that was completed =\< 14 prior to registration
* Pregnant women
* Nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study medication; adequate contraception is defined as 2 methods of birth control (e.g., hormonal contraceptives, intrauterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide) or prior surgical sterilization, or abstinence from heterosexual activity
* Prior treatment with ibrutinib or prior exposure to BTK inhibitors
* Uveal melanoma
* Current use of warfarin or other vitamin K antagonists
* Require continuous treatment with a strong CYP3A inhibitor
* Currently participating or has participated in a study of an investigational cancer therapy agent or using an investigational device within 28 days prior to study registration
* Live vaccines within 28 days prior to study pre-registration
* Invasive surgical procedure within 28 days prior to study pre-registration
* History of clinically severe (e.g., requires chronic immunosuppressive therapy, \[e.g., cyclosporine A, tacrolimus\]) autoimmune disease (e.g., ulcerative colitis, lupus), or history of organ transplant
* Known history of human immunodeficiency virus (HIV) infection, active infection with hepatitis B virus or hepatitis C virus, or any uncontrolled active systemic infection
* Gastrointestinal disease that might inhibit ibrutinib absorption (e.g., malabsorption syndrome, resection of the stomach or a large portion of small bowel, or partial/complete bowel obstruction), or unable to swallow capsules
* Active central nervous system metastases and/or carcinomatous meningitis
* Note: Patients with untreated brain metastasis will be excluded; patients with previously treated brain metastases may participate provided they meet the following criteria:
* Inactive (without evidence of progression which is documented by CT or MRI within 90 days prior to registration), AND
* On =\< 10 mg/day prednisone or equivalent for at least 28 days prior pre-registration
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Clinically significant cardiovascular disease such as unstable angina, myocardial infarction, or acute coronary syndrome within =\< 180 days prior to registration, symptomatic or uncontrolled arrhythmia, congestive heart failure, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
* Other active malignancy =\< 3 years prior to pre-registration; note: if there is a history of prior malignancy, the patient must not be receiving other specific treatment for cancer
* EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix
* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome =\< 6 months prior to pre-randomization
* Known bleeding disorders (von Willebrand's disease or hemophilia)
* History of ischemic stroke or intracranial hemorrhage =\< 180 days prior to pre-registration
* Currently active, clinically significant hepatic impairment Child-Pugh class A, B or C according to the Child Pugh classification
* REGISTRATION- EXCLUSION
* Failure to confirm histologically or cytologically unresectable stage III or metastatic melanoma (stage IV) not amenable to local therapy
* Prior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody \[mAb\]) =\< 28 days prior to registration
* Received a strong cytochrome P450 (CYP) 3A inhibitor =\< 7 days prior to registration
* Concurrent systemic immunosuppressant therapy =\< 21 days prior to registration
* Recent infection requiring systemic antibiotic treatment that was completed =\< 14 prior to registration
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Matthew S. Block, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic in Rochester
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Yao Y, Yan Y, Suman VJ, Dietz AB, Erskine CL, Dimou A, Markovic SN, McWilliams RR, Montane HN, Block MS. Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma. Front Immunol. 2025 Feb 4;16:1491448. doi: 10.3389/fimmu.2025.1491448. eCollection 2025.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://www.mayo.edu/research/clinical-trials
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2017-00079
Identifier Type: REGISTRY
Identifier Source: secondary_id
16-002462
Identifier Type: OTHER
Identifier Source: secondary_id
MC1577
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
NCT01708941
ACTIVE_NOT_RECRUITING
PHASE2
Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma
NCT04967196
TERMINATED
PHASE1
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
NCT02723006
TERMINATED
PHASE1
A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma
NCT03698019
ACTIVE_NOT_RECRUITING
PHASE2
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06961006
RECRUITING
PHASE2
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
NCT02362594
ACTIVE_NOT_RECRUITING
PHASE3
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma
NCT04207086
ACTIVE_NOT_RECRUITING
PHASE2
Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
NCT00289640
COMPLETED
PHASE2
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
NCT06284590
RECRUITING
PHASE2
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
NCT00636168
COMPLETED
PHASE3
A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma
NCT00289627
COMPLETED
PHASE2
Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma
NCT01676649
ACTIVE_NOT_RECRUITING
PHASE2
Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
NCT02581930
ACTIVE_NOT_RECRUITING
PHASE2
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
NCT02970981
COMPLETED
PHASE2
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
NCT04462406
RECRUITING
PHASE2
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
NCT03873818
COMPLETED
PHASE2
PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
NCT01621490
COMPLETED
PHASE1
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
NCT04708418
ACTIVE_NOT_RECRUITING
PHASE2
Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification
NCT02812693
WITHDRAWN
PHASE1/PHASE2
Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
NCT02599402
COMPLETED
PHASE3
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614
ACTIVE_NOT_RECRUITING
PHASE2
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
NCT05926960
ACTIVE_NOT_RECRUITING
PHASE2
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
NCT02388906
COMPLETED
PHASE3